Omeros FY2025 EPS Estimate Raised by Cantor Fitzgerald

Omeros Co. (NASDAQ:OMER) – Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings estimates for Omeros in a report released on Monday, May 19th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will earn ($2.04) per share for the year, up from their prior forecast of ($2.19). The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

Several other equities analysts also recently weighed in on the company. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Monday. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Friday, May 16th. Finally, D. Boral Capital restated a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Omeros currently has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Omeros Stock Down 0.9%

Shares of NASDAQ OMER opened at $3.29 on Wednesday. The firm has a market cap of $191.83 million, a price-to-earnings ratio of -1.42 and a beta of 2.42. Omeros has a 52-week low of $2.97 and a 52-week high of $13.60. The business’s 50 day moving average is $6.88 and its two-hundred day moving average is $8.13.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Trexquant Investment LP acquired a new stake in shares of Omeros in the 1st quarter worth $88,000. Hsbc Holdings PLC acquired a new stake in Omeros during the first quarter worth about $142,000. Wellington Management Group LLP acquired a new stake in Omeros in the 1st quarter valued at $1,118,000. Nuveen LLC purchased a new position in Omeros in the 1st quarter worth approximately $938,000. Finally, Invesco Ltd. increased its stake in Omeros by 169.1% during the 1st quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock worth $716,000 after buying an additional 54,696 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.